BioCryst Reports Second Quarter 2019 Financial Results
New drug application for once-daily oral BCX7353 for prophylaxis of hereditary angioedema attacks on-track for submission in Q4 2019
Data from ongoing Phase 1 trial of oral Factor D inhibitor, BCX9930, expected in Q4 2019
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the second quarter ended June 30, 2019 and provided a corporate update.
"We have just returned from the 2...